Price ambition is only defensible when the evidence can carry it Manufacturers can no longer r...
Read morePricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...
Read moreAt the start of 2026, we identified five key pharmaceutical pricing and market access trends expecte...
Read moreEarly HTA scientific advice reduces price and reimbursement risk by informing ev...
Read moreWhile missing an EU Joint Scientific Consultation (JSC) is suboptimal, the greater strategic concern...
Read moreFrom 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...
Read moreOur previous article explored how TrumpRx might influence drug pricing in the US, the potential ...
Read moreManufacturers looking to optimise access for their orphan drugs need to navigate a complex environme...
Read moreIn 2026, U.S. policy shifts will link domestic US prices to internatio...
Read moreThe year 2026 marks a significant milestone for the European Union’s (EU) Health Tec...
Read more